1. Netherlands Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
argenx SE

argenx SE

ARGNF
argenx SEUS flagOther OTC
835.00
USD
- -
- -
51.67BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.24
0.6
0.48
0.82
1.78
0.68
2.03
0.91
9.74
7.55
21.45
36.59
67.76
75.11
Basic EPS, GAAP
-0.54
-1.66
-1.06
-1.19
-1.37
-2.12
-4.69
-13.4
-7.99
-13.05
-5.16
13.92
21.08
23.99
Free Cash Flow per Basic Share
-0.59
-0.87
-0.99
0.54
-1.8
-1.73
2.72
-8.89
-14.26
-17.78
-8.12
-2.52
9.36
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-2.2
-5.51
-3.44
-3.94
-4.75
-5.28
-9.79
-21.72
-27.29
-38.67
-41.94
-26.14
-4.44
- -
Tangible Book Value per Share
1.91
8.06
2.59
3.54
16.81
17.12
29.4
33.18
46.26
48.52
69.48
88.83
115.03
- -
Basic Weighted Avg Shares
16
8
16
19
25
36
39
45
51
54
57
60
61
62
Sales/Revenue/Turnover
4
5
7
15
44
25
78
41
497
411
1,226
2,190
4,153
4,661
Operating Margin (%)
-232.69
-286.02
-227.68
-145.56
-62.97
-381.01
-255.04
-1,165.21
-72.37
-176.24
-34.3
-0.81
25.39
28.05
Depreciation Expense
- -
- -
- -
- -
1
1
2
4
6
104
111
18
28
- -
Net Income, GAAP
-8
-13
-17
-22
-34
-76
-181
-608
-408
-710
-295
833
1,292
1,489
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.91
Profit Margin (%)
-229.03
-274.6
-223.4
-145.27
-77.1
-310.22
-230.95
-1,475.29
-82.1
-172.76
-24.06
38.03
31.11
31.94
Working Capital
29
60
39
73
411
609
1,363
1,729
2,242
2,472
3,701
4,213
5,579
- -
LT Debt
- -
- -
- -
- -
- -
- -
5
6
8
9
15
33
36
- -
Total Equity
30
61
41
67
414
616
1,180
1,674
2,534
2,814
4,098
5,498
7,323
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-73.21
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
11
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
36
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
62
- -
Market Capitalization
41,579
45,169
38,246

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
- -
6,899
- -
Cash, Cash Equivalents & STI
- -
4,440
- -
Accounts Receivable, Net
- -
1,490
- -
Inventories
- -
474
- -
Total Current Liabilities
- -
1,320
- -
Payables & Accruals
- -
695
- -
ST Debt
- -
11
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
94.21%
35.08%
33.19%
Free Cash Flow
-189.63%
-97.19%
-479.69%
Net Income, GAAP
23.92%
-68.95%
55.1%
Sales/Revenue/Turnover
187.2%
291.02%
89.64%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
401
478
573
738
2,190
2025
790
948
1,127
1,288
4,153
2026
1,298
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-1.04
- -
1.52
- -
13.92
2025
2.77
- -
- -
- -
21.08
2026
5.9
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Timothy Van Hauwermeiren
Full Time Employees
1,599
Sector
Healthcare
Industry
Biotechnology
Address
Willemstraat 5 Breda Netherlands 4811 AH
IPO Date
Apr 30, 2015
Website
argenx.com
Similar Companies
Regenicin, Inc. (RGIN)
PureTech Health plc (PRTC.L)
EvoNext Holdings S.A. (EVE.SW)
Estrella Immunopharma, Inc. (ESLA)
Verrica Pharmaceuticals Inc. (VRCA)
Intech Biopharm Corporation (6461.TWO)
Business
argenx SE, a global immunology company headquartered in Amsterdam, Netherlands, and founded in 2008, develops and commercializes antibody-based therapies targeting severe autoimmune diseases; its lead product, VYVGART (efgartigimod), an FcRn inhibitor available in intravenous and subcutaneous formulations including VYVGART Hytrulo and pre-filled syringe, treats generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP); the company advances a broad pipeline through its Immunology Innovation Program (IIP), encompassing candidates like ARGX-109, ARGX-213, and ARGX-121 in clinical stages for additional autoimmune indications such as primary immune thrombocytopenia (ITP), thyroid eye disease, and Sjogren's syndrome, with out-licensed assets including LP0145 (ARGX-112) to LEO Pharma, ARGX-115 (ABBV-151) to AbbVie, and collaborations with Genmab. argenx operates across the United States, Europe, Japan, China, and emerging markets including the Gulf region via partners like Zai Lab and Genpharm, serving patients and healthcare providers with precision medicines derived from proprietary antibody engineering platforms. Recent developments include expansion of the global collaboration with Halozyme Therapeutics in September 2024 to six targets incorporating ENHANZE drug delivery technology; a new strategic partnership with Unnatural Products in 2025 to develop oral peptides; an expanded manufacturing agreement with FUJIFILM for a North Carolina facility supporting efgartigimod supply; regulatory progress with Phase 1 data for ARGX-109 expected in late 2025 and further topline results for pipeline programs through 2026; and robust commercial growth with global VYVGART net sales reaching $949 million in Q2 2025, up 97% year-over-year, alongside FDA PDUFA target for VYVGART SC pre-filled syringe in April 2025.

Company News

APIChat